177 related articles for article (PubMed ID: 37509605)
41. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
42. Therapeutic opportunities in cancer therapy: targeting the p53-MDM2/MDMX interactions.
Munisamy M; Mukherjee N; Thomas L; Pham AT; Shakeri A; Zhao Y; Kolesar J; Rao PPN; Rangnekar VM; Rao M
Am J Cancer Res; 2021; 11(12):5762-5781. PubMed ID: 35018225
[TBL] [Abstract][Full Text] [Related]
43. The MDM4/MDM2-p53-IGF1 axis controls axonal regeneration, sprouting and functional recovery after CNS injury.
Joshi Y; Sória MG; Quadrato G; Inak G; Zhou L; Hervera A; Rathore KI; Elnaggar M; Cucchiarini M; Marine JC; Puttagunta R; Di Giovanni S
Brain; 2015 Jul; 138(Pt 7):1843-62. PubMed ID: 25981963
[TBL] [Abstract][Full Text] [Related]
44. NDRG4 is a novel oncogenic protein and p53 associated regulator of apoptosis in malignant meningioma cells.
Kotipatruni RP; Ren X; Thotala D; Jaboin JJ
Oncotarget; 2015 Jul; 6(19):17594-604. PubMed ID: 26053091
[TBL] [Abstract][Full Text] [Related]
45. Mdm2 Splice isoforms regulate the p53/Mdm2/Mdm4 regulatory circuit via RING domain-mediated ubiquitination of p53 and Mdm4.
Fan C; Wang X
Cell Cycle; 2017 Apr; 16(7):660-664. PubMed ID: 28166445
[TBL] [Abstract][Full Text] [Related]
46. The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Cancer Res Commun; 2022 Sep; 2(9):1075-1088. PubMed ID: 36922937
[TBL] [Abstract][Full Text] [Related]
47. The long and the short of it: the MDM4 tail so far.
Haupt S; Mejía-Hernández JO; Vijayakumaran R; Keam SP; Haupt Y
J Mol Cell Biol; 2019 Mar; 11(3):231-244. PubMed ID: 30689920
[TBL] [Abstract][Full Text] [Related]
48. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development.
Migliorini D; Lazzerini Denchi E; Danovi D; Jochemsen A; Capillo M; Gobbi A; Helin K; Pelicci PG; Marine JC
Mol Cell Biol; 2002 Aug; 22(15):5527-38. PubMed ID: 12101245
[TBL] [Abstract][Full Text] [Related]
49. Regulation of MDM4.
Markey MP
Front Biosci (Landmark Ed); 2011 Jan; 16(3):1144-56. PubMed ID: 21196223
[TBL] [Abstract][Full Text] [Related]
50. Mdm2 and Mdm4 loss regulates distinct p53 activities.
Barboza JA; Iwakuma T; Terzian T; El-Naggar AK; Lozano G
Mol Cancer Res; 2008 Jun; 6(6):947-54. PubMed ID: 18567799
[TBL] [Abstract][Full Text] [Related]
51. Downregulation of microRNA-23b protects against ischemia-reperfusion injury via p53 signaling pathway by upregulating MDM4 in rats.
Zhao Z; Guan JZ; Wu M; Lai GH; Zhu ZL
J Cell Biochem; 2019 Mar; 120(3):4599-4612. PubMed ID: 30537038
[TBL] [Abstract][Full Text] [Related]
52. miR-661 downregulates both Mdm2 and Mdm4 to activate p53.
Hoffman Y; Bublik DR; Pilpel Y; Oren M
Cell Death Differ; 2014 Feb; 21(2):302-9. PubMed ID: 24141721
[TBL] [Abstract][Full Text] [Related]
53. Synergistic regulation of p53 by Mdm2 and Mdm4 is critical in cardiac endocardial cushion morphogenesis during heart development.
Zhang Q; He X; Chen L; Zhang C; Gao X; Yang Z; Liu G
J Pathol; 2012 Nov; 228(3):416-28. PubMed ID: 22821713
[TBL] [Abstract][Full Text] [Related]
54. MDM4 (MDMX) overexpression enhances stabilization of stress-induced p53 and promotes apoptosis.
Mancini F; Gentiletti F; D'Angelo M; Giglio S; Nanni S; D'Angelo C; Farsetti A; Citro G; Sacchi A; Pontecorvi A; Moretti F
J Biol Chem; 2004 Feb; 279(9):8169-80. PubMed ID: 14660608
[TBL] [Abstract][Full Text] [Related]
55. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
[TBL] [Abstract][Full Text] [Related]
56. MDM4 alternative splicing and implication in MDM4 targeted cancer therapies.
Wu J; Lu G; Wang X
Am J Cancer Res; 2021; 11(12):5864-5880. PubMed ID: 35018230
[TBL] [Abstract][Full Text] [Related]
57. Mdm4 loss in mice expressing a p53 hypomorph alters tumor spectrum without improving survival.
Fang M; Simeonova I; Bardot B; Lejour V; Jaber S; Bouarich-Bourimi R; Morin A; Toledo F
Oncogene; 2014 Mar; 33(10):1336-9. PubMed ID: 23474762
[TBL] [Abstract][Full Text] [Related]
58. MDM4 is a key therapeutic target in cutaneous melanoma.
Gembarska A; Luciani F; Fedele C; Russell EA; Dewaele M; Villar S; Zwolinska A; Haupt S; de Lange J; Yip D; Goydos J; Haigh JJ; Haupt Y; Larue L; Jochemsen A; Shi H; Moriceau G; Lo RS; Ghanem G; Shackleton M; Bernal F; Marine JC
Nat Med; 2012 Aug; 18(8):1239-47. PubMed ID: 22820643
[TBL] [Abstract][Full Text] [Related]
59. The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor.
Eskandari M; Shi Y; Liu J; Albanese J; Goel S; Verma A; Wang Y
Leuk Lymphoma; 2021 Jan; 62(1):167-175. PubMed ID: 32924682
[TBL] [Abstract][Full Text] [Related]
60. Methylation of p14(ARF) gene in meningiomas and its correlation to the p53 expression and mutation.
Amatya VJ; Takeshima Y; Inai K
Mod Pathol; 2004 Jun; 17(6):705-10. PubMed ID: 15073599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]